Business

Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer

Neil T. Mason, MBA; Jason M. Burkett, CPA, MACC; Ryan S. Nelson, PharmD; Julio M. Pow-Sang, MD; Robert A. Gatenby, MD; Timothy Kubal, MD, MBA; John W. Peabody, MD, PhD; G. Douglas Letson, MD; Howard L. McLeod, PharmD; Jingsong Zhang, MD, PhD

Business, Original Research

Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States

Luis Hernandez, MSc, MPH; Anshul Shah, BS Pharm, MS; Qi Zhao, MD; Dejan Milentijevic, PhD, MBA; Akshay Kharat, PhD

Business, Original Article

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S. Broder, MD, MSHS; Qiufei Ma, PhD; Tingjian Yan, PhD; Jie Zhang, PhD; Eunice Chang, PhD; David Kuzan, MD; Lamis Eldjerou, MD

Business, Original Research

A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice

Victoria K. Karschney; David R. Greeley, MD, FAAN

Business, Original Research

Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports

Jean A. Gerlach; Brian Snow, PharmD; Katherine M. Prioli, MS; Ronald Vertsman, PharmD; Julie Patterson, PharmD, PhD; Laura T. Pizzi, PharmD, MPH

Business, Original Research

Knee Osteoarthritis Treatment Costs in the Medicare Patient Population

Gerard Malanga, MD; Faizan Niazi, PharmD; Vasco Deon Kidd, DHSc, MPH, MS, PA-C; Edmund Lau, MS; Steven M. Kurtz, PhD; Kevin L. Ong, PhD, PE; Andrew L. Concoff, MD, FACR, CAQSM

Business, Original Research

Budget Impact Analysis of a Home-Based Nutrition Program for Adults at Risk for Malnutrition

Suela Sulo, PhD, MSc; David Lanctin, MPH; Josh Feldstein, BA; Bjoern Schwander, MA, RN; Jamie Partridge, PhD, MBA; Wendy Landow, MPH; York F. Zöllner, MSc

Business, Original Research

Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018

Zizi Elsisi, BPharm; Ana L. Hincapie, PhD; Jeff Jianfei Guo, BPharm, PhD

Stakeholder Perspective

Utilization Challenges of Drugs for Multiple Sclerosis in a Medicaid Population

James T. Kenney, RPh, MBA

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH; Elizabeth Marrett, MPH; Xian Shen, PhD, MS, BS; Winghan Jacqueline Kwong, PharmD, PhD; Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

Atheer A. Kaddis, PharmD